pharma · Facioscapulohumeral Muscular Dystrophy (FSHD) · Facioscapulohumeral Muscular Dystrophy 1 (FSHD1) · FULC
Fulcrum Therapeutics
Fulcrum Therapeutics is a pharma organization headquartered in Cambridge, USA. It trades on NYSE under ticker FULC. Primary therapeutic focus areas include Facioscapulohumeral Muscular Dystrophy (FSHD), Facioscapulohumer
26 Landsdowne St, Cambridge, Massachusetts 02139, US HQ
2016 Founded
73 Employees
Public company Type
FULC · NYSE Ticker
Company details
- Status
- Public
- HQ
- 26 Landsdowne St, Cambridge, Massachusetts 02139, US
- Founded
- 2016
- Employees
- 73
- Programs
- 12
- Drugs
- 8
- Patents
- 11
Losmapimod
Phase 3 · small molecule · Facioscapulohumeral Muscular Dystrophy (FSHD)
Losmapimod for Facioscapulohumeral Muscular Dystrophy (FSHD) is a Phase 3 program (small_molecule) at Fulcrum Therapeutics with 2 ClinicalTrials.gov record(s).
Internal code FIS-002-2019 OLE
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Fulcrum Therapeutics
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Facioscapulohumeral Muscular Dystrophy (FSHD)
- Status
- terminated
- Trials
- 2